Immunotherapies for drug addictions;Inmunoterapias para las adicciones a las drogas

Adicciones

Volumn 20, Issue 2, 2008, Pages 111-116

  Montoya, Iván D ^a  

^a Natonal Institute on Drug Abuse   (United States)

Author keywords

Cocaine; Drug abuse; Immunotherapy; Nicotine; Treatment; Vaccine

Indexed keywords

AMFEBUTAMONE; BUPRENORPHINE; METHADONE; METHAMPHETAMINE; MONOCLONAL ANTIBODY; MORPHINE; NALTREXONE; NIC 002; NICOTINE VACCINE; PHENCYCLIDINE; PLACEBO; TA NIC; VARENICLINE;

ACTIVE IMMUNIZATION; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; DRUG DEPENDENCE; DRUG HALF LIFE; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HEROIN DEPENDENCE; HUMAN; IMMUNOTHERAPY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OPIATE ADDICTION; PASSIVE IMMUNIZATION; REVIEW; RISK BENEFIT ANALYSIS; TOBACCO DEPENDENCE;

EID: 46749088251     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.274     Document Type: Review

References (15)

1. Vocci F, Ling W. Medications development: successes and challenges. Pharmacol.Ther. 2005; 108: 94-108.
2. Reducing tobacco use: a report of the Surgeon General-executive summary. Nicotine.Tob. Res. 2000; 2: 379-395.
3. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284: 1689-1695.
4. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch. Neurol. 2007; 64: 1575-1579.
5. Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacol.Ther. 2005; 108: 76-85.
6. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974; 252: 708-710.
7. Bradbury MW, Lightman SL. The blood-brain interface. Eye 1990; 4 (Pt 2): 249-254.
8. Owens SM. Antibodies as pharmacokinetic and metabolic modifiers of neurotoxicity. NIDA Res.Monogr 1997; 173: 259-272.
9. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, Horwith G, Pentel PR. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin.Pharmacol.Ther. 2005; 78: 456-467.
10. Kosten TR. Future of anti-addiction vaccines. Stud. Health Technol.Inform. 2005; 118:177-185.
11. Elkashef A, Biswas J, Acri JB, Vocci F. Biotechnology and the treatment of addictive disorders: new opportunities. BioDrugs. 2007; 21:.259-267.
12. Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR. The future of vaccines in the management of addictive disorders. Curr.Psychiatry Rep. 2007; 9: 381-387.
13. Nabi Biopharmaceuticals. Website: www.nabi.com . Consulted on February 26, 2008.
14. LeSage MG, Keyler DE, Hieda Y, Collins G, Burroughs D, Le C, Pentel PR. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl) 2006; 184:.409-416.
15. Pentel P, Malin D. A vaccine for nicotine dependence: targeting the drug rather than the brain. Respiration 2002; 69:.193-197.